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We applaud the authors and editors of this second issue 
of the Medical Hypothesis, Discovery, and Innovation 
Ophthalmology Journal in 2013 for presenting new 
research and innovative ideas on the vast array of issues 
and diseases related to ocular health. In its scope as a 
peer-reviewed journal, it covers articles and studies from 
leading causes of preventable blindness to promising 
advanced medical therapies. The content focuses on 
difficult-to-treat diseases that encourage us as eye care 
professionals to think outside the box, or in our case, slit 
lamp. We hope that such progressive thinking regarding 
visual impairment can be extended outside the clinical 
setting and into the communities, the schools, the 
nursing facilities, and homes of the patient population. 
Below we discuss the VISION 2020 program global 
activities in the prevention of blindness. 
This current issue presents a review of promising 
research in the use stem cell therapy to restore retinitis 
pigmentosa, which currently is an untreatable condition 
[1]. Another potentially innovative treatment for a 
technically complex ocular problem, intracorneal rings 
for keratoconus, is discussed by Ibrahim et al [2]. In this 
issue, there are two trials reviewed that explore the use 
of ozone therapy in dry age-related macular 
degeneration (AMD) [3], which is a global public health 
problem and one of the three main causes of blindness 
[3]. Despite skepticism from the medical community, it is 
heartening to see the positive results of ozone therapy 
which has improved the vision of patients almost blind 
from dry AMD. Dry AMD is a disease that is highly 
prevalent among the aging population and does not yet 
have an effective therapy (unlike wet AMD for which we 
have an increasing arsenal of treatment options).   Long-
term follow-up and more confirmation studies are 
required to validate the viability of ozone therapy as a 
treatment of dry AMD.  
The pathogenesis and treatment intervention of another 
major, global cause of blindness is also addressed in this 
issue. Like AMD, glaucoma is a blinding disease that has 
less effective and costly treatment options, is 
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multifactorial, and is progressive to the point of 
irreversible blindness. Shahsuvaryan reviewed the role of 
neuroprotective agents, mainly the potential of calcium 
channel blockers to mitigate retinal ganglion cell death in 
patients with glaucoma, and concluded that 
neuroprotection may be a beneficial adjunctive therapy 
along with intra-ocular pressure control [4]. 
Finally, we find it especially worthy to mention the case 
study presented in this issue on the combination therapy 
of intravitreal bevacizumb and photocoagulation applied 
to a 56-year old woman in Argentina who had Eales 
disease, which provides a patient-centered approach to a 
difficult and recurring condition [5]. The authors noted 
that during her follow-up process, optical coherence 
tomography and angiography were not carried out due 
to her financial constraints. Fortunately for the patient, 
this case study ended on a positive note with the disease 
stabilized, visual acuity improved, and recurrence not 
evident after four years. Unfortunately, these results are 
not attainable for many people with visual impairment, 
because they cannot afford or have limited access to eye 
care. This particular case illustrates the reality of the so-
called “personalized” medical care, but it also 
unfortunately reveals that despite the relative affluence 
in a country such as Argentina, there are still barriers to 
eye health services. What could we then expect for other 
lesser developed countries?   
Four out of five people lose their sight unnecessarily, 
even in today’s world, where 80% of blindness can be 
treated, cured, and/or prevented. The sad reality is that 
blindness remains a disease of poverty with 90% of 
people with blindness living in developing countries, 
where all aspects of health care is often simply not a 
government funding priority. Although much of the 
global blindness prevention effort is geared towards the 
aging population, statistics prove that one child becomes 
blind every minute. There are 6 million visually-impaired 
children in the world; 80% of whom live in developing 
countries. Most of these children will die from other 
causes within the first year. Improved access to 
affordable eye care is urgently needed across the globe 
to protect the millions each year who needlessly go 
blind. In a responsible global world, efforts need to be 
made to ensure a future of universal eye health 
coverage, which should be a fundamental human right. 
VISION 2020: The Right to Sight (V2020) is a global 
program that was established in partnership in 1999 by 
the International Agency for the Prevention of Blindness 
(IAPB) and the World Health Organization (WHO) with 
the joint goal to eliminate avoidable blindness by 2020. 
V2020 is supported worldwide by governments and 
health ministries, non-governmental organizations 
(NGOs), eye care professionals, program managers, and 
industry that together contribute to the planning, 
development, and implementation of sustainable 
national eye care programs. These programs are based 
on the three core pillars of disease control, human 
resource development and infrastructure development, 
and the incorporation of the principles of primary health 
care. National committees for the prevention of 
blindness have been formed with members from both 
the private and public sectors in over 80 countries.  
Recent global data from the WHO show that blindness 
and visual impairment have been reduced globally by 9%, 
or 26 million people, since 2004 [6]. This is a remarkable 
achievement in spite of the fact that the age group most 
affected by visual impairment (>50 years) has increased 
by 14% in this time frame. Yet, challenges remain in the 
fight against avoidable blindness, as the WHO estimates 
that 285 million people worldwide still have visual 
impairment, and 39 million people are blind. As of 2010, 
the WHO confirmed that the 3 leading global causes of 
blindness are cataracts, glaucoma, and AMD [6]. 
However, diabetes is now a global public health crisis, 
and diabetic retinopathy, a complication of the disease 
that leads to blindness, is emerging as a priority of 
blindness prevention. Uncorrected refractive errors, 
although quickly solved with an eye examination and eye 
glasses, are the main cause for moderate to severe visual 
impairment.   
Again, the reduction in the global cases of blindness and 
visual impairment is a significant achievement of V2020, 
which promotes advocacy, carries out relevant research 
on ophthalmology and public health, and promotes 
Community Eye Health (CEH) through workshops, 
training, and partnerships with international, regional, 
and local ophthalmologic societies. With seven years to 
go, V2020 has proven to be a successful platform to 
launch and coordinate blindness prevention activities. 
However, there is still much work to be done in regions 
like Latin America, where despite the last decades  of 
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increased blindness prevention activities, we still find 
that more than 60% of the population does not have 
access to eye care. Although there has been an increase 
in cataract surgical rates in recent years, the key to 
successful blindness prevention is coverage. Eye care 
services coverage is a satisfactory 80% in Latin American 
cities, but only 10% in rural areas.  
We conducted a recent review of the social determinants 
of blindness and visual impairment so as to better 
understand how social determinants based on gender, 
socioeconomic status, ethnicity, race, living in a specific 
geographic region, or having a specific health condition 
influenced the prevalence of visual impairment and 
blindness [7]. We found these social determinants are 
indicative of the social inequalities often observed in 
blindness and visual impairment, which cause the 
disparities in access and coverage of eye health across 
certain populations or groups. An example would be the 
rural, indigenous communities in Latin America, who do 
not have access to eye care. Our review produced four 
important findings: (1) women have a higher prevalence 
of visual impairment and blindness, (2) a higher 
socioeconomic status was inversely associated with 
prevalence of blindness or visual impairment, (3) 
ethnicity and race were associated with visual 
impairment, and (4) geographic inequalities were 
observed to be related to income level and living in a 
rural area [7]. To overcome the great inequality in the 
provision of eye care and extend coverage to the 
vulnerable and underserved populations that are 
affected by these social determinants of eye health, we 
and supporters of V2020 plan to scale-up regional 
programs. To do so, we will start by increasing cataract 
surgical output, increasing efficiency, decreasing costs, 
and transitioning local eye care programs to become 
sustainable and systematically integrated into the 
population’s country health care programs. We can only 
attain goals such as these with the provision of proper 
training and comprehensive education to residents and 
other eye care professionals to better balance the poor 
geographic distribution of manpower and infrastructure 
across regions. That way, eye care professionals can work 
with or establish successful and sustainable programs 
that maximize impact and service delivery to the globe’s 
underserved populations and minimize cost to eliminate 
barriers to eye care. 
CEH training is one of the most important V2020 
activities and has demonstrated positive impact and 
results since program inception. In another recent paper 
[8], we discuss the adoption of CEH training in the 
residency curriculum of the International Council of 
Ophthalmology in 2012. CEH training, as a result of 
V2020 activity, has also been included in regional and 
national residency curricula and programs, including the 
Pan American Association of Ophthalmology curriculum 
and residency programs in Brazil, Chile, and Mexico. In 
our paper [8], we show how more CEH training is still 
needed for the future with the number of individuals 
aged ≥60 years is increasing twice as fast as the number 
of ophthalmologists, which forebodes greater difficulty in 
the future as this aging global population will need 
access to eye care. We advocate for the need to train 
more ophthalmologists and other eye care professionals 
to advance the V2020 initiative. At the core of CEH 
training is the need to change behaviors of 
ophthalmologists so that they better meet the needs of 
their local population base and community. In many 
developing countries, this means the promotion of high 
volume and cost-effective cataract surgery (where many 
ophthalmologists currently do not operate or operate on 
a very limited number of cataracts). A CEH curriculum is 
based on the principles of public health and is not only 
about increasing patient-centered approaches of 
ophthalmologists to eye care. V2020 also offers CEH 
management courses and a Masters in Science in CEH at 
the International Centre of Eye Health of the London 
School of Hygiene and Tropical Medicine. These courses 
focus on manpower and management training through a 
systematic, integrated approach to managing 
comprehensive eye care programs and include the 
relevant issues of financial planning, fundraising, and 
human resources. The ultimate goal of these courses is 
to have able manpower to strengthen regional and 
national eye care systems through holistic integration of 
eye care in the general health systems.  
Global and regional data indicate decreasing trends in 
blindness and visual impairment, but in order for V2020 
to be successful in just seven years time, more 
likeminded eye care professionals working to provide 
better coverage and accessibility are needed so that no 
patient is turned away from treatment and becomes 
needlessly blind. We hope that this journal’s readers will 
 
 
MEHDI Ophthalmol 2013; Vol. 2, No 2  
 
29 VISION 2020: THE RIGHT TO SIGHT IN 7 YEARS? 
especially consider our message and join us in the fight 
against avoidable blindness. For further information, 
please refer to the V2020 website: www.iapb.org/vision-
2020. Finally, we extend our gratitude and appreciation 
to the Medical Hypothesis, Discovery, and Innovation 
Journal for providing us this opportunity to share our 
research and experience with V2020. 
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